Sign in
Taking people in United StatesPhase 2

Studies brain cholinergic nerve health in adults with Down syndrome using a scan

Uses a radiotracer scan to assess brain cholinergic nerve health in adults with Down syndrome.

Key facts

Who runs it
Vanderbilt University Medical Center
Where
Nashville, United StatesSee the site
Trial code
Registry title
Cholinergic Integrity in Down Syndrome in Association With Aging, Alzheimer's Disease Pathology, and Cognition
Status
Recruiting
Phase
Phase 2
People taking part
30 people, planned
Started
19 Aug 2021
Expected to end
30 Apr 2027
Type of study
Interventional
Treatments tested
  • [18F]-FEOBV Radiotracer
Record updated
22 June 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults aged 18-55 with Down syndrome and no dementia. It uses brain scans and tests to study the brain's cholinergic system, which matters for memory and attention.

Age
18 to 55 years
Sex
Men and women
Disease stage
Down syndrome, including mosaic Down syndrome or partial trisomy 21. No diagnosis of dementia. Mental age of 4 years or more.
Earlier treatment
Medicines that act on the brain must have been at a stable dose for at least 4 weeks.

Main reasons for not taking part

  • Diagnosis of dementia
  • Cannot have MRI or PET scans, for example with a pacemaker or cochlear implant
  • IQ less than 40
  • Pregnancy or breast-feeding
  • Another cancer within the last 5 years, with a few skin and in situ exceptions

This trial only enrols participants with Down syndrome. The registry sentence this rests on: Diagnosis of Down syndrome (DS), including mosaic DS or partial trisomy 21.

The registry criteria, word for word

Show all 23 criteriaShow less

Who can take part

  • Diagnosis of Down syndrome (DS), including mosaic DS or partial trisomy 21
  • Provision of signed and dated informed consent form and if needed, assent with signed consent by a legally authorized representative (LAR)
  • Stated willingness to comply with all study procedures and availability for the duration of the study
  • Male or female, aged 18-55 inclusive
  • In good general health as evidenced by medical history with no diagnosis of dementia
  • Permitted CNS-active medications, stable in dose for at least 4 weeks or longer. If new medications have been started, the medical monitoring team will review on case-by-case basis to recommend timing of baseline cognitive testing
  • Adequate visual and auditory acuity to allow neuropsychological testing
  • For females who are not surgically sterile or post-menopausal by two years: negative pregnancy test 24 hours prior to PET scan
  • Mental Age of 4 years or greater (based upon the Kaufman Brief Intelligence Test, 2nd Edition)
  • English must be first/native language
  • Reliable Study Partner (may be caregiver, sibling, parent) who can provide information about the subject's clinical symptoms and history

Who cannot take part

  • Participants in whom magnetic resonance imaging (MRI) is contraindicated including, but not limited to, those with a pacemaker, presence of metallic fragments near the eyes or spinal cord, or cochlear implant (Dental fillings do not present a risk for MRI)
  • Concurrent participation in a clinical trial for an investigational product or concurrent participation in a longitudinal study with overlapping outcome measures/procedures is prohibited
  • Any significant disease or unstable medical condition that could affect neuropsychological testing (i.e., unstable cardiac problems, chronic renal failure, chronic hepatic disease, severe pulmonary disease)
  • History within the last 5 years of a primary or recurrent malignant disease with the exception of non-melanoma skin cancers, resected cutaneous squamous cell carcinoma in situ, basal cell carcinoma, cervical carcinoma in situ, or in situ prostate cancer with normal prostate-specific antigen post-treatment
  • Clinical diagnosis of dementia
  • For participants undergoing CSF collection: a current blood clotting or bleeding disorder, or significantly abnormal PT or PTT at screening or if on anti-coagulation (e.g warfarin)
  • Participants unable to complete MRI and PET procedures
  • IQ less than 40 (as assessed by Kaufman Brief Intelligence Test, Second Edition (KBIT-2)
  • Pregnancy, breast-feeding
  • Clinically significant abnormalities in B12 or TFTs that might interfere with the study. A low B12 is exclusionary unless follow-up labs (homocysteine (HC) and methylmalonic acid (MMA)) indicate that it is not physiologically significant. A high TSH is exclusionary unless follow-up T3/T4 levels indicate that it is not physiologically significant
  • Clinically significant abnormalities in screening laboratories
  • Participants whom the Site PI deems to be otherwise ineligible

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 55 years old?

Where in United States

  • Vanderbilt University Medical Center Clinical Research CenterNashville, United StatesContact: Amy BoegelTaking people

About the trial

What the trial wants to find out

Progressive age-related cognitive deficits occurring in both AD and DS have been connected to the degeneration of several neuronal populations, but mechanisms are not fully elucidated. The most consistent neuronal losses throughout the progression of AD are seen in cholinergic neurons where these losses negatively affect cognition, particularly in attention, learning, and memory formation. Evidence of reduced cholinergic integrity in DS is largely limited to animal models and post-mortem human data. The investigators propose to use molecular, functional, and structural biomarkers to assess the cholinergic integrity in adults with DS. The investigators anticipate using the data gathered in this pilot study to inform future study designs to determine AD risk stratification in DS by identifying individuals who show an accelerated decline in cholinergic integrity that correlates with cognitive and neurobehavioral changes. Also, our cholinergic biomarkers may identify whether individuals with DS are likely to respond to pro-cholinergic interventions, including the novel cholinergic modulators that are being developed to enhance cholinergic-sensitive cognitive functioning. The investigators anticipate using the data gathered here to inform future treatment studies in TRC-DS and beyond where novel cholinergic treatments may offer opportunities for early intervention in DS and be complementary to disease-modifying approaches such as anti-amyloid treatments.

The group in the trial

  • Down SyndromeTreatment being tested

    Adults between 18-55 with Down Syndrome.

    Treatment: [18F]-FEOBV Radiotracer

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Cholinergic Integrity in Down Syndrome in Association With Aging, Alzheimer's Disease Pathology, and Cognition
Plain-language title
Studies brain cholinergic nerve health in adults with Down syndrome using a scanGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Fit questions
Built from NCT05231798, who can take part
Record updated
22 June 2026